Regeneron Pharmaceuticals | REGN

Stock Price
993.18
Daily Change
14.11 1.44%
Monthly
3.69%
Yearly
32.38%
Q2 Forecast
974.18
Peers Price Chg Day Year Date
Kyowa Hakko Kirin 2,680.50 25.00 0.94% -2.74% Jun/03
Astellas Pharma 1,557.50 9.00 0.58% -31.91% Jun/03
AbbVie 160.25 -0.29 -0.18% 17.09% Jun/03
Agios Pharmaceuticals 41.83 5.49 15.11% 62.70% Jun/03
Alnylam Pharmaceuticals 149.56 1.13 0.76% -20.73% Jun/03
Amgen 307.57 2.09 0.68% 38.62% Jun/03
AstraZeneca 12,373.00 183.00 1.50% 4.91% Jun/03
Biogen 228.84 3.84 1.71% -24.26% Jun/03
BioMarin Pharmaceutical 77.47 2.40 3.20% -12.23% Jun/03
Bristol-Myers Squibb 41.77 0.69 1.68% -36.69% Jun/03
Gilead Sciences 63.67 -0.54 -0.84% -16.45% Jun/03
GlaxoSmithKline 1,600.00 -166.50 -9.43% 15.77% Jun/03
Incyte 58.80 1.00 1.72% -4.41% Jun/03
Ionis Pharmaceuticals 38.99 1.42 3.78% -7.74% Jun/03
J&J 147.73 1.02 0.70% -4.41% Jun/03
Eli Lilly 831.96 10.26 1.25% 87.27% Jun/03
Merck 127.97 2.52 2.01% 15.36% Jun/03
Moderna 146.36 3.96 2.78% 13.88% Jun/03
Neurocrine Biosciences 139.05 3.64 2.69% 52.48% Jun/03
Novartis 92.71 -0.25 -0.27% 2.58% Jun/03
Novartis 103.07 0.02 0.02% 6.14% Jun/03
Opthea 0.52 0.01 0.98% -11.21% Jun/03
Pfizer 29.24 0.65 2.27% -24.35% Jun/03
Ultragenyx Pharmaceutical 40.85 0.71 1.76% -17.67% Jun/03
Regeneron Pharmaceuticals 993.18 14.11 1.44% 32.38% Jun/03
Roche Holding 231.40 0.40 0.17% -20.60% Jun/03
Sanofi 49.15 0.14 0.29% -2.60% Jun/03
Sarepta Therapeutics 124.17 -5.70 -4.39% -0.09% Jun/03
Teva Pharmaceutical Industries 6,333.00 89.00 1.43% 132.83% Jun/03
United Therapeutics 276.95 1.82 0.66% 29.73% Jun/03
Vertex Pharmaceuticals 468.09 13.15 2.89% 39.97% Jun/03

Indexes Price Day Year Date
US500 5271 -6.20 -0.12% 23.34% Jun/03
USND 16787 52.30 0.31% 26.89% Jun/03
US100 18565 28.67 0.15% 27.54% Jun/03

Regeneron Pharmaceuticals traded at $993.18 this Monday June 3rd, increasing $14.11 or 1.44 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals gained 3.69 percent. Over the last 12 months, its price rose by 32.38 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 974.18 by the end of this quarter and at 956.46 in one year, according to Trading Economics global macro models projections and analysts expectations.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.